News

HealthDay on MSN20h
Blood-Based Screening Has Acceptable Accuracy for Colorectal Cancer Detection
A blood-based test has acceptable accuracy for colorectal cancer detection but not for advanced precancerous lesions in an ...
The American Journal of Managed Care13d
FIT Outperforms Blood-Based cfDNA Test in Detecting Precancerous Colorectal Lesions
Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal ...
A new blood test can tell if cancer has returned months before a scan
New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...
Medical Device Network on MSN9d
Guardant Health’s MCD test earns FDA breakthrough designation
Guardant Health's Shield multi-cancer detection (MCD) test has secured the US Food and Drug Administration’s (FDA) ...
Guardant Health Wins Fast Company’s 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...
The American Journal of Managed Care10d
Blood Test Detects 79% of Colorectal Cancers in Screening Study
A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.
The Bakersfield Californian10d
FDA Grants Breakthrough Device Designation to Guardant Health’s Shield Multi-Cancer Detection (MCD) Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.
Freenome posts pivotal liquid biopsy data as FDA filing nears completion
Freenome has published data in JAMA from the pivotal trial of its blood-based test for colorectal cancer. The paper, which ...